Plasma-derived cell-free small non-coding RNAs are promising non-invasive biomarkers for cancer detection and monitoring. However, variability in sequencing output limits standardization, and cross-platform performance for plasma small RNA profiling has not been systematically evaluated. Illumina short-read sequencing is the current standard, whereas the newcomer, Ultima-Genomics platform, has been less extensively studied for circulating small RNA in plasma. To directly compare platform performance, we sequenced plasma cell-free RNA from 39 patients with pancreatic cancer and 39 matched controls on both platforms. After filtering, Ultima-Genomics retained more mature microRNA reads, whereas Illumina achieved slightly higher enrichment efficiency and mapping rates. Despite these technical differences, both platforms produced concordant expression profiles, with strong cross-platform correlations for shared microRNAs and clear separation of cases and controls within each dataset. Differential expression analysis identified 14 significant microRNAs on both platforms with concordant directions of change, most of which are supported by pancreatic cancer databases. Pathway enrichment analysis highlighted signaling pathways implicated in pancreatic cancer, supporting the biological relevance of both shared and platform-specific signatures. These findings indicate that both Illumina and Ultima Genomics platforms are suitable for plasma small RNA profiling and capture biologically relevant signals in pancreatic cancer.
Levon, A., Volkov, H., Shlayem, R., Shomron, N.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 0
- Comments 0